79 related articles for article (PubMed ID: 20130109)
1. Modelling the likely effect of the increase of the upper age limit from 70 to 73 for breast screening in the UK National Programme.
Duffy SW; Sasieni P; Olsen AH; Cafferty FH
Stat Methods Med Res; 2010 Oct; 19(5):547-55. PubMed ID: 20130109
[TBL] [Abstract][Full Text] [Related]
2. Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group.
Lynge E
APMIS Suppl; 1998; 83():1-44. PubMed ID: 9850674
[TBL] [Abstract][Full Text] [Related]
3. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods.
Mandelblatt J; Schechter CB; Lawrence W; Yi B; Cullen J
J Natl Cancer Inst Monogr; 2006; (36):47-55. PubMed ID: 17032894
[TBL] [Abstract][Full Text] [Related]
4. Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme.
McCann J; Treasure P; Duffy S
J Med Screen; 2004; 11(3):117-25. PubMed ID: 15333269
[TBL] [Abstract][Full Text] [Related]
5. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
6. Modelling the impact of changes in sensitivity on the outcomes of the UK breast screening programme.
Taylor P
J Med Screen; 2010; 17(1):31-6. PubMed ID: 20356943
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of modelling mammography screening strategies.
Yaffe MJ; Mittmann N; Lee P; Tosteson AN; Trentham-Dietz A; Alagoz O; Stout NK
Health Rep; 2015 Dec; 26(12):9-15. PubMed ID: 26676234
[TBL] [Abstract][Full Text] [Related]
8. Trends in aggregate cancer incidence rates in relation to screening and possible overdiagnosis: a word of caution.
Duffy SW; Michalopoulos D; Sebuødegård S; Hofvind S
J Med Screen; 2014 Mar; 21(1):24-9. PubMed ID: 24446330
[TBL] [Abstract][Full Text] [Related]
9. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England.
Duffy SW; Tabar L; Olsen AH; Vitak B; Allgood PC; Chen TH; Yen AM; Smith RA
J Med Screen; 2010; 17(1):25-30. PubMed ID: 20356942
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of breast cancer screening in women on dialysis.
Wong G; Howard K; Chapman JR; Craig JC
Am J Kidney Dis; 2008 Nov; 52(5):916-29. PubMed ID: 18789566
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation.
Arrospide A; Rue M; van Ravesteyn NT; Comas M; Larrañaga N; Sarriugarte G; Mar J
BMC Cancer; 2015 Oct; 15():671. PubMed ID: 26459293
[TBL] [Abstract][Full Text] [Related]
12. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer.
Duffy SW; Agbaje O; Tabar L; Vitak B; Bjurstam N; Björneld L; Myles JP; Warwick J
Breast Cancer Res; 2005; 7(6):258-65. PubMed ID: 16457701
[TBL] [Abstract][Full Text] [Related]
13. Modelling the effect of breast cancer screening on related mortality using French data.
Uhry Z; Hédelin G; Colonna M; Asselain B; Arveux P; Exbrayat C; Guldenfelds C; Soler-Michel P; Molinié F; Trétarre B; Rogel A; Courtial I; Danzon A; Guizard AV; Ancelle-Park R; Eilstein D; Duffy S
Cancer Epidemiol; 2011 Jun; 35(3):235-42. PubMed ID: 21159568
[TBL] [Abstract][Full Text] [Related]
14. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography.
Morrell S; Barratt A; Irwig L; Howard K; Biesheuvel C; Armstrong B
Cancer Causes Control; 2010 Feb; 21(2):275-82. PubMed ID: 19894130
[TBL] [Abstract][Full Text] [Related]
15. The effect of service screening on breast cancer mortality rates.
Cox B
Eur J Cancer Prev; 2008 Aug; 17(4):306-11. PubMed ID: 18562953
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of breast cancer screening policies using simulation.
Gocgun Y; Banjevic D; Taghipour S; Montgomery N; Harvey BJ; Jardine AK; Miller AB
Breast; 2015 Aug; 24(4):440-8. PubMed ID: 25866350
[TBL] [Abstract][Full Text] [Related]
18. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
[TBL] [Abstract][Full Text] [Related]
20. Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975-2006.
Otten JD; Broeders MJ; Fracheboud J; Otto SJ; de Koning HJ; Verbeek AL
Int J Cancer; 2008 Oct; 123(8):1929-34. PubMed ID: 18688863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
